Cambrex Corporation (NYSE:CBM) VP Samantha Hanley sold 14,000 shares of Cambrex Corporation stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $57.56, for a total transaction of $805,840.00. Following the sale, the vice president now owns 1,500 shares of the company’s stock, valued at approximately $86,340. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Cambrex Corporation (NYSE:CBM) traded up 0.26% on Monday, reaching $57.95. 282,935 shares of the company traded hands. The firm has a 50 day moving average of $54.99 and a 200-day moving average of $53.85. Cambrex Corporation has a one year low of $38.30 and a one year high of $62.95. The stock has a market capitalization of $1.89 billion, a PE ratio of 22.06 and a beta of 2.42.

Cambrex Corporation (NYSE:CBM) last released its earnings results on Thursday, May 4th. The biotechnology company reported $0.68 earnings per share for the quarter, beating analysts’ consensus estimates of $0.51 by $0.17. The business had revenue of $105.01 million during the quarter, compared to the consensus estimate of $99.05 million. Cambrex Corporation had a net margin of 17.36% and a return on equity of 24.92%. The company’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.50 EPS. On average, analysts anticipate that Cambrex Corporation will post $3.02 EPS for the current year.

Insider Buying and Selling by Quarter for Cambrex Corporation (NYSE:CBM)

ILLEGAL ACTIVITY NOTICE: This piece of content was posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/06/12/cambrex-corporation-cbm-vp-samantha-hanley-sells-14000-shares.html.

CBM has been the topic of several recent analyst reports. ValuEngine lowered shares of Cambrex Corporation from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. BidaskClub raised shares of Cambrex Corporation from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, Zacks Investment Research raised shares of Cambrex Corporation from a “hold” rating to a “buy” rating and set a $59.00 price objective on the stock in a research note on Thursday, May 11th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Cambrex Corporation presently has a consensus rating of “Buy” and a consensus target price of $64.00.

A number of hedge funds have recently added to or reduced their stakes in the stock. Flinton Capital Management LLC increased its stake in Cambrex Corporation by 3.8% in the first quarter. Flinton Capital Management LLC now owns 1,870 shares of the biotechnology company’s stock worth $103,000 after buying an additional 68 shares in the last quarter. YorkBridge Wealth Partners LLC increased its stake in Cambrex Corporation by 20.2% in the first quarter. YorkBridge Wealth Partners LLC now owns 1,874 shares of the biotechnology company’s stock worth $106,000 after buying an additional 315 shares in the last quarter. Meeder Asset Management Inc. purchased a new stake in Cambrex Corporation during the first quarter worth $109,000. Dubuque Bank & Trust Co. purchased a new stake in Cambrex Corporation during the first quarter worth $144,000. Finally, Ameritas Investment Partners Inc. purchased a new stake in Cambrex Corporation during the first quarter worth $151,000. 98.28% of the stock is owned by institutional investors and hedge funds.

About Cambrex Corporation

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.